Two four-marker haplotypes on 7q36.1 region indicate that the potassium channel gene HERG1 (KCNH2, Kv11.1) is related to schizophrenia: a case control study
© Atalar et al; licensee BioMed Central Ltd. 2010
Received: 12 December 2009
Accepted: 28 May 2010
Published: 28 May 2010
The pathobiology of schizophrenia is still unclear. Its current treatment mainly depends on antipsychotic drugs. A leading adverse effect of these medications is the acquired long QT syndrome, which results from the blockade of cardiac HERG1 channels (human ether-a-go-go-related gene potassium channels 1) by antipsychotic agents. The HERG1 channel is encoded by HERG1 (KCNH2, Kv11.1) gene and is most highly expressed in heart and brain. Genetic variations in HERG1 predispose to acquired long QT syndrome. We hypothesized that the blockade of HERG1 channels by antipsychotics might also be significant for their therapeutic mode of action, indicating a novel mechanism in the pathogenesis of schizophrenia.
We genotyped four single nucleotide polymorphisms (SNPs) in 7q36.1 region (two SNPs, rs1805123 and rs3800779, located on HERG1, and two SNPs, rs885684 and rs956642, at the 3'-downstream intergenic region) and then performed single SNP and haplotype association analyses in 84 patients with schizophrenia and 74 healthy controls after the exclusion of individuals having prolonged or shortened QT interval on electrocardiogram.
Our analyses revealed that both genotype and allele frequencies of rs3800779 (c.307+585G>T) were significantly different between populations (P = 0.023 and P = 0.018, respectively). We also identified that two previously undescribed four-marker haplotypes which are nearly allelic opposite of each other and located in chr7:150225599-150302147bp position encompassing HERG1 were either overrepresented (A-A-A-T, the at-risk haplotype, P = 0.0007) or underrepresented (C-A-C-G, the protective haplotype, P = 0.005) in patients compared to controls.
Our results indicate that the potassium channel gene HERG1 is related to schizophrenia. Our findings may also implicate the whole family of HERG channels (HERG1, HERG2 and HERG3) in the pathogenesis of psychosis and its treatment.
Schizophrenia (SCH) is a serious mental disorder affecting around 0.5% of the general population worldwide . Despite being a clinically recognized entity for more than a century, the etiopathogenesis of SCH still remains a mistery [1, 2]. SCH seems to be a multifactorial disorder, in which the contribution of both genetic and environmental factors and their interplay are important [1, 3]. Little is known about the underlying environmental factors, and the rare genetic variants so far disclosed as susceptibility factors are neither necessary nor sufficient for the disease . As yet, there is no identified biological marker with which a biologically valid diagnosis can be made [1, 2]. The current treatment depends on antipsychotic drugs which have antidopaminergic properties (D2 receptor blockade) as the main feature, with or without a certain degree of additional antiserotonergic effects (5-HT2A receptor blockade) in particular [4, 5]. The high remission but low recovery rate by antipsychotic therapy [6, 7] is probably due to their insufficient specificity for the complex mechanism underlying SCH, which might go beyond the most frequently-described hyperdopaminergic pathophysiology [2, 8]. The unspecificity in dopaminergic-blocking effects of antipsychotic drugs also seems to be the cause of their main side-effects, the extrapyramidal syndromes (EPS) [9, 10]. A further leading drug-induced adverse effect is the acquired long QT (LQT) syndrome, which results from the blockade of a type of voltage-gated potassium channel in the heart, namely the cardiac HERG1 (human ether-a-go-go-related gene potassium channel 1) channel, by antipsychotic agents [11–13].
An old and enduring notion in psychiatry is that the therapeutic and adverse effects of antipsychotic drugs frequently co-occur [32, 33], indicating that they work through more or less similar or overlapping mechanisms. This is true in the case of their antidopaminergic properties which produce therapeutic effects on one hand, but cause EPS side effects on the other [10, 34]. By analogy, we hypothesized that the blockade of HERG1 channels by antipsychotics, which is responsible for the acquired LQT side effects, might also be involved in the therapeutic mechanism of these drugs, thereby providing a clue to the core pathogenesis of SCH. We therefore studied a number of genetic variations in and around the HERG1 gene by single SNP and haplotype association analyses in a population of patients with SCH. Recently, Huffaker et al.  studied two family-based cohorts of European ancestry and three case-control cohorts also of European ancestry (Germans, Armenians and Italians). They identified six single nucleotide polymorphisms (SNPs) to be associated with SCH in family-based studies, four SNPs in the German case-control study and four SNPs in the meta-analysis including all five clinical data sets, and reported HERG1 as a previously undescribed potential susceptibility gene for SCH .
Patients and controls
The study population consisted of 87 unrelated Turkish male inpatients with SCH (mean age = 34,91 ± 6,98 years) recruited from the Bakirkoy Research and Training Hospital for Psychiatry, Neurology and Neurosurgery (BRSHH) in Istanbul, a specialized referral center of the Turkish Ministry of Health. The inclusion criteria were to be aged between 18 and 65 years, to have an informed written consent by themselves and/or by their legal supervisors and to have a diagnosis of SCH. The diagnosis of SCH was made in accordance with the Diagnostic and Statistical Manual of Mental Disorders - Fourth Edition (DSM-IV) in consensus by two psychiatrists who interviewed the patients independently using the Structured Clinical Interview for DSM-IV (SCID-I)  Cases were screened to exclude substance-induced psychotic disorder, psychosis due to a general medical condition, and co-morbid psychiatric disorder. The control population included 77 Turkish males (mean age = 34,23 ± 8,20 years) collected from the Control Subjects Biobank at the Research Institute for Experimental Medicine of Istanbul University. None of the controls in that biobank has a known or identified psychiatric disorder, neurological disease or medical condition. Patients and controls were recruited from Istanbul metropolitan area. Both study populations do well represent the general population of Turkey as Istanbul receives substantial internal migration from almost all regions of Turkey since 1950s.
Exclusion of subjects with a long or short QT interval on electrocardiogram (ECG)
As many genetic variations in the HERG1 gene are related with congenital or acquired forms of LQT and SQT syndromes, we excluded the patients and controls that had a prolonged or shortened QT interval on their ECG recordings (the main diagnostic criterium for LQT or SQT syndromes, respectively ) in order to discard any incidental confounding effect which could arise from a putative HERG1-LQT/SQT association rather than a real HERG1-SCH relationship. A standard 12-lead resting ECG was obtained from each patient and control with an automated electrocardiograph (ECG-9620 Cardifax, Nihan Kohden, Japan) at a paper speed of 25 mm/s. The QT interval and the so-derived QTc value (corrected QT according to heart rate by the Bazett's formula [29, 37], QTc = QT/√RR) were measured automatically by the Modular ECG Analysis System (MEANS). In the international guidelines [38, 39] or related literature [13, 29], the widely accepted threshold values are QTc > 450 ms in men for prolonged QT interval and QTc < 300 ms for shortened QT interval. ECG recordings of the patients and controls were evaluated accordingly, and three patients and three controls having QTc > 450 ms or < 300 ms were excluded. The remaining 84 patients (mean age = 34,37 ± 6,70 years) and 74 controls (mean age = 34,32 ± 8,11 years) formed the ultimate study groups.
Selection of single nucleotide polymorphisms (SNPs) for association analyses
DNA extraction and SNP genotyping
Genomic DNA was extracted from 10 ml fresh peripheral blood using the QIAamp DNA Blood Mini Kit (Qiagen, Germany) according to the manifacturer's protocol. Twenty microliters of genomic DNA from each patient and control subject were prepared at a concentration of 2 ng/L in v-bottomed 96-well microtitre plates. Repeat and blank samples were also included in the plates as experimental controls. The microtitre plates were then transported to the KBiosciences Company, Cambridge, UK, via a private courier and in accordance with the national and international legal regulations and technical requirements for international transfer of biological materials. All of the genotyping was performed by the KBiosciences using the KASP technology, which is a competitive allele-specific PCR incorporating a FRET quencher cassette, according to the protocol used by the company .
Statistics for single SNP and haplotype association analyses
Deviations from Hardy-Weinberg Equilibrium (HWE) were assessed for quality control of genotyping procedures among patients and controls separately. SNPs were excluded from the analysis if they were out of HWE (P < 0.05) or had a minor allele frequency of less than 5%. The allele and genotype frequencies were obtained by direct counting. We used SPSS 11.5 software for statistical analyses. The P values were corrected by means of Bonferroni correction for multiple testing. We used Haploview software  to reconstruct haplotypes and estimate haplotype frequencies in the unrelated patients and controls. In order to obtain a measure of significance corrected for multiple testing, we ran 10000 permuations to compute P values using the Haploview program. Comparisons of the distributions of the allele, genotype and haplotype frequencies were performed using the chi-square test. Statistical significance was defined as P < 0.05.
This study was approved by the Ethics Committee of BRSHH, and was in compliance with the World Medical Association (WMA) Declaration of Helsinki. Written informed consent was obtained from all subjects and/or their legal supervisors.
Single SNP association analysis
Genotype and allele frequencies and results of the association analysis between patients and controls.
Genotype frequencies, n (%)
SCH (n = 84)
CTR (n = 74)
SCH (n = 84)
CTR (n = 74)
Haplotype association analysis
Four-SNP haplotype frequencies and results of the association analysis between patients and controls.
Case, control ratios
In this study, we reasoned that a particular mechanism (HERG1 channel blockade, for example) responsible for a prevailing adverse effect of antipsychotic drugs (acquired LQT in this case) is also likely to be one unique mechanism by which their therapeutic effects are mediated, and that, by inference, this might contribute to our understanding of the underlying mechanisms in SCH. This assumption led us to investigate the putative association of HERG1 gene with SCH. To discard any incidental confounding association of HERG1 with LQT or SQT syndromes among study and control populations, we excluded those patients and controls with LQT or SQT intervals on ECG. We chose the SNPs to be analyzed (two located on HERG1 and two at the 3'-downstream region of the gene) on the basis of their association with QT interval prolongation according to a large-scale, two-step design, population-based European study . Our analyses revealed that two haplotypes, which were nearly allelic opposite of each other and composed of the four SNPs investigated, were either overrepresented (A-A-A-T, the at-risk haplotype) or underrepresented (C-A-C-G, the protective haplotype) in patients with SCH as compared to control subjects. Because the relevant haplotype block which spans a ~76 kb region of genomic DNA in chr7:150225599-150302147 bp position does not include any other genes, this finding might be essentially attributed to either HERG1 or its surrounding regulatory sequences. In support of this, we report that one of the two SNPs located on HERG1 (rs3800779 in the intron 2, c.307+585G>T) shows significant differences in both genotype and allele distributions between patients and controls. Our results thereby identify the HERG1 gene as a susceptibility factor for SCH and implicate the contribution of HERG1 channels to its pathobiology.
Despite intensive research, the pathobiology of SCH still remains obscure [1, 2]. The bulk of current evidence gathered from a wide range of studies suggests that SCH is a disorder of neurodevelopment involving the dysfunction of multiple neurotransmitters in neural circuits particularly concerning the dopaminergic, serotonergic, glutamatergic and GABAergic systems within or between cortical-prefrontal and subcortical-limbic regions [2, 7, 43, 44]. The biological characteristics of HERG channels are broadly in concordance with the above-mentioned features of SCH pathobiology. ERG1 (this is homologous to the human gene HERG1, referring its orthologs in all species) is expressed at high levels throughout the brain besides the heart, specifically, in the hippocampus, neocortex, hypothalamus, thalamus, amygdala, substantia nigra, red nucleus and cerebellum [22, 23, 25, 45, 46]. The other two members of the ERG genes family, ERG3 and ERG2 (homologous terms in all species for HERG3 and HERG2, respectively), also have a more or less widespread expression in the brain [22, 23, 45, 46] and moreover they seem to be nervous system-specific . There is convincing evidence that the products of these three genes form heterotetramers in various combinations at specific brain regions where they co-expressed [45–48], giving rise to multiple heterotetrameric ERG channels with functional properties distinct from those of homotetramers [21, 47–49]. All types of ERG channels studied so far, and particularly the most studied ERG1 channels, were shown to modify neuronal excitability and spike frequency adaption [49–53]. ERG1 gene was consistently shown to be expressed in dopaminergic  and serotonergic  neurons from rat brain and in GABAergic interneurons from mouse  and rat brains [22, 46]. It is of particular note that both an experimental study  and a computational model  showed the modulation of dopamine neurons by ERG channels. The neuronal expression of all three ERG genes, in particular including the most studied ERG1, was found to be developmentally regulated [23, 56].
Recently, Huffaker et al.  reported HERG1 as a previously undescribed potential susceptibility gene for SCH. The authors genotyped, in a family-based association study, the haplotype-tagging SNPs in 10 previously reported candidate genes and their results revealed the 7q36.1 region to be strongly associated with SCH. They then performed initial studies of 43 or 40 SNPs in the 7q36.1 region of two family-based cohorts of European ancestry. Subsequently, seven SNPs in HERG1, selected according to initial results, were analyzed in three case-control cohorts, also of European ancestry (Germans, Armenians and Italians). They identified six SNPs to be associated with SCH in family-based studies, four SNPs in the German case-control study and four SNPs in the meta-analysis including all five clinical data sets, although none of the SNPs were significant in the Armenian and Italian samples. Interestingly, across all their samples, the HERG1 SNP most strongly associated with SCH was rs3800779, which is also the SNP showing unique significance towards the same direction of association in our study. Nevertheless, their three-marker haplotype analysis did not show an association that was more significant than individual SNPs. The authors also investigated HERG1 expression in brain and found expression of full-length isoform 1A (KCNH2-1A or HERG1-1A) to be significantly lower in patients with SCH than in controls, but they were unable to detect an association with the HERG1 risk genotypes that they identified. Following further investigation aimed at determining the apparently complicated gene processing, they ultimately discovered a previously undescribed brain-specific isoform (KCNH2-3.1 or HERG1-3.1) which lacks the first two exons and introns of the full-length gene but contains the downstream region. Furthermore, they determined that expression of HERG1-3.1 was increased in brain of patients compared to controls and that this was significantly associated with HERG1 risk genotypes. Taken together, the authors argued that overexpression of this newly identified isoform is related to the pathogenesis of SCH, and that the mechanism by which the disease-associated SNPs contribute to increased risk involves the regulation of HERG1-3.1 transcription by a splicing mechanism yet to be determined.
Our study also justifies the usefulness of our preliminary rationale envisaging that both an adverse and a therapeutic effect of antipsychotic drugs might depend on a common mechanism, which could enhance our knowledge about the pathobiology of SCH. Although for many years it was believed that the prevalent EPS side effects and the therapeutic effects of antipsychotic drugs could not be dissociated since the former effects were assumed to be required for the latter effects [33, 59], the recent introduction of more specific second generation antipsychotic drugs implied otherwise [33, 60]. Thereby, our findings suggest that whilst the blockade of cardiac HERG1 channels by antipsychotic agents causes acquired LQT side effects, the blockade of neuronal HERG1 channels by these drugs might contribute to their therapeutic effects, as previously proposed by a number of authors [35, 61–63]. Consistently, our findings might have considerable impact on antipsychotic treatment in clinical practice. Firstly, HERG1 gene variations might predict the efficacy of an antipsychotic drug in a given patient, in addition to determining the predisposition of an individual to acquired LQT syndrome. Secondly, the introduction of more specific antipsychotic drugs that preferentially block neuronal rather than cardiac HERG1 channels might reduce the occurrence of acquired LQT side effects in patients without worsening therapeutic benefits. Thirdly, specific neuronal HERG1 channel modifiers could also be developed for the treatment of SCH in conjunction with antipsychotic drugs in order to improve the therapeutic outcome. Finally, we propose that a specific neuronal HERG modifier, especially for HERG3 or HERG2 channels, might be a more effective and safer pharmacological intervention than others  in primary prevention of SCH at high-risk individuals.
One limitation of our study is its moderate sample size. Although the number of our study subjects is generally regarded as small for association studies, we were able to confirm the findings reported in larger populations by Huffaker et al.  regarding the association of SCH with HERG1 and specifically the HERG1 SNP rs3800779. Nevertheless, our study needs to be reproduced in a larger sample size regarding the identification of two previously undescribed haplotypes located on 7q36.1 region encompassing HERG1 and more significantly associated with SCH than individual SNP.
A further limitation of our study is the lack of details on the ethnic characteristics of our samples. Indeed, considerable mixtures between ethnicities for many generations prevent to have precise data on the exact ethnic origins of many people in Turkey. Nevertheless, both patients and controls were recruited from Istanbul metropolitan area, and we believe that both populations do well represent the general population of Turkey and that a possibility of stratification between populations does not exist in our samples.
In summary, we have found that a SNP (rs3800779, c.307+585G>T) located on HERG1 shows significant differences in both genotype and allele distributions between patients with SCH and control subjects, and we have also identified two previously undescribed four-marker haplotypes located on 7q36.1 region in chr7:150225599-150302147 bp position encompassing HERG1 and more significantly associated with SCH than individual SNP (the at-risk haplotype A-A-A-T and the protective haplotype C-A-C-G, which are nearly allelic opposite of each other). Our results indicate that the potassium channel gene HERG1 is associated with SCH, although this needs to be reproduced in a larger sample size and in other ethnic groups. Nevertheless, we believe our findings merit further investigation in order to determine whether the HERG1 gene is also a common susceptibility factor to psychosis including affective disorders besides SCH, considering that genetic associations are generally not specific to one of the traditional diagnostic categories of functional psychoses . Finally, as the other two members of the ERG channels family, ERG3 and ERG2, which are known for their widespread expression in brain, are seemingly nervous system-specific  and form heterotetramers with ERG1 channels [45–48], we believe that HERG3 and HERG2 genes also need to be extensively studied in psychotic disorders. Future research, most importantly a combinatoric approach  integrating the genetics (genetic variation, genetic regulation and epigenetic modification) and the biology (synthesis, trafficking, gating and conductance) of HERG channels with clinical data, will illuminate their exact lieu in the pathobiology and treatment of SCH and psychosis.
This work was funded by Istanbul University Research Projects Unit (BAP) Grant 149/20082003. We thank Yucel Erbilgin and Suzin Catal for their technical assistance. We are grateful to Prof. Nick Craddock for his critical reading of the manuscript and constructive comments.
- Tandon R, Keshavan MS, Nasrallah HA: Schizophrenia, "just the facts": what we know in 2008. 2. Epidemiology and etiology. Schizophr Res. 2008, 102: 1-18. 10.1016/j.schres.2008.04.011.View ArticlePubMedGoogle Scholar
- Keshavan MS, Tandon R, Boutros NN, Nasrallah HA: Schizophrenia, "just the facts": what we know in 2008. Part 3: neurobiology. Schizophr Res. 2008, 106: 89-107. 10.1016/j.schres.2008.07.020.View ArticlePubMedGoogle Scholar
- Murray RM, Lappin J, Di Forti M: Schizophrenia: from developmental deviance to dopamine dysregulation. Eur Neuropsychopharmacol. 2008, 18 (Suppl 3): S129-S134. 10.1016/j.euroneuro.2008.04.002.View ArticlePubMedGoogle Scholar
- Agid O, Kapur S, Remington G: Emerging drugs for schizophrenia. Expert Opin Emerg Drugs. 2008, 13: 479-495. 10.1517/14728220.127.116.119.View ArticlePubMedGoogle Scholar
- Horacek J, Bubenikova-Valesova V, Kopecek M, Palenicek T, Dockery C, Mohr P, Hoschl C: Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs. 2006, 20: 389-409. 10.2165/00023210-200620050-00004.View ArticlePubMedGoogle Scholar
- Abi-Dargham A, Laruelle M: Mechanisms of action of second generation antipsychotic drugs in schizophrenia: insights from brain imaging studies. Eur Psychiatry. 2005, 20: 15-27. 10.1016/j.eurpsy.2004.11.003.View ArticlePubMedGoogle Scholar
- Jarskog LF, Miyamoto S, Lieberman JA: Schizophrenia: new pathological insights and therapies. Annu Rev Med. 2007, 58: 49-61. 10.1146/annurev.med.58.060904.084114.View ArticlePubMedGoogle Scholar
- Meisenzahl EM, Schmitt GJ, Scheuerecker J, Moller HJ: The role of dopamine for the pathophysiology of schizophrenia. Int Rev Psychiatry. 2007, 19: 337-345. 10.1080/09540260701502468.View ArticlePubMedGoogle Scholar
- Dayalu P, Chou KL: Antipsychotic-induced extrapyramidal symptoms and their management. Expert Opin Pharmacother. 2008, 9: 1451-1462. 10.1517/14656518.104.22.1681.View ArticlePubMedGoogle Scholar
- Pani L, Pira L, Marchese G: Antipsychotic efficacy: relationship to optimal D2-receptor occupancy. Eur Psychiatry. 2007, 22: 267-275. 10.1016/j.eurpsy.2007.02.005.View ArticlePubMedGoogle Scholar
- Recanatini M, Poluzzi E, Masetti M, Cavalli A, De Ponti F: QT prolongation through hERG K+ channel blockade: current knowledge and strategies for the early prediction during drug development. Med Res Rev. 2005, 25: 133-166. 10.1002/med.20019.View ArticlePubMedGoogle Scholar
- Roden DM, Viswanathan PC: Genetics of acquired long QT syndrome. J Clin Invest. 2005, 115: 2025-2032. 10.1172/JCI25539.PubMed CentralView ArticlePubMedGoogle Scholar
- Stollberger C, Huber JO, Finsterer J: Antipsychotic drugs and QT prolongation. Int Clin Psychopharmacol. 2005, 20: 243-251. 10.1097/01.yic.0000166405.49473.70.View ArticlePubMedGoogle Scholar
- Warmke JW, Ganetzky B: A family of potassium channel genes related to eag in Drosophila and mammals. Proc Natl Acad Sci USA. 1994, 91: 3438-3442. 10.1073/pnas.91.8.3438.PubMed CentralView ArticlePubMedGoogle Scholar
- Gutman GA, Chandy KG, Grissmer S, Lazdunski M, McKinnon D, Pardo LA, Robertson G, Rudy B, Sanguinetti M, Stuhmer W, Wang X: International Union of Pharmacology LIII: nomenclature and molecular relationships of voltage-gated potassium channels. Pharmacol Rev. 2005, 57: 473-508. 10.1124/pr.57.4.10.View ArticlePubMedGoogle Scholar
- Schwarz JR, Bauer CK: Functions of erg K+ channels in excitable cells. J Cell Mol Med. 2004, 8: 22-30. 10.1111/j.1582-4934.2004.tb00256.x.View ArticlePubMedGoogle Scholar
- Vandenberg JI, Torres AM, Campbell TJ, Kuchel PW: The HERG K+ channel: progress in understanding the molecular basis of its unusual gating kinetics. Eur Biophys J. 2004, 33: 89-97. 10.1007/s00249-004-0419-y.View ArticlePubMedGoogle Scholar
- Wehrens XHT: Structural determinants of potassium channel blockade and drug-induced arrhythmias. Handb Exp Pharmacol. 2005, 171: 123-157. full_text.View ArticleGoogle Scholar
- Jenkinson DH: Potassium channels: multiplicity and challenges. Br J Pharmacol. 2006, 147 (Suppl 1): S63-S71. 10.1038/sj.bjp.0706447.PubMed CentralPubMedGoogle Scholar
- Tamargo J, Caballero R, Gomez R, Valenzuela C, Delpon E: Pharmacology of cardiac potassium channels. Cardiovasc Res. 2004, 62: 9-33. 10.1016/j.cardiores.2003.12.026.View ArticlePubMedGoogle Scholar
- Wimmers S, Wulfsen I, Bauer CK, Schwarz JR: Erg1, erg2 and erg3 K channel subunits are able to form heteromultimers. Pflugers Arch. 2001, 441: 450-455. 10.1007/s004240000467.View ArticlePubMedGoogle Scholar
- Papa M, Boscia F, Canitano A, Castaldo P, Sellitti S, Annunziato L, Taglialatela M: Expression pattern of the ether-a-gogo-related (ERG) K+ channel-encoding genes ERG1, ERG2, and ERG3 in the adult rat central nervous system. J Comp Neurol. 2003, 466: 119-135. 10.1002/cne.10886.View ArticlePubMedGoogle Scholar
- Polvani S, Masi A, Pillozzi S, Gragnani L, Crociani O, Olivotto O, Becchetti A, Wanke E, Arcangeli A: Developmentally regulated expression of the mouse homologues of the potassium channel encoding genes m-erg1, m-erg2 and m-erg3. Gene Expr Patterns. 2003, 3: 767-776. 10.1016/S1567-133X(03)00124-8.View ArticlePubMedGoogle Scholar
- Shi W, Wymore RS, Wang HS, Pan Z, Cohen IS, McKinnon D, Dixon JE: Identification of two nervous system-specific members of the erg potassium channel gene family. J Neurosci. 1997, 17: 9423-9432.PubMedGoogle Scholar
- Wymore RS, Gintant GA, Wymore RT, Dixon JE, McKinnon D, Cohen IS: Tissue and species distribution of mRNA for the IKR-like K+ channel, erg. Circ Res. 1997, 80: 261-268.View ArticlePubMedGoogle Scholar
- Thomas D, Karle CA, Kiehn J: The cardiac hERG/IKr potassium channel as pharmacological target: structure, function, regulation, and clinical applications. Curr Pharm Des. 2006, 12: 2271-2283. 10.2174/138161206777585102.View ArticlePubMedGoogle Scholar
- Witchel HJ: The hERG potassium channel as a therapeutic target. Expert Opin Ther Targets. 2007, 11: 321-336. 10.1517/1472822.214.171.1241.View ArticlePubMedGoogle Scholar
- Hancox JC, McPate MJ, El Harchi A, Zhang YH: The hERG potassium channel and hERG screening for drug-induced torsades de pointes. Pharmacol Ther. 2008, 119: 118-132. 10.1016/j.pharmthera.2008.05.009.View ArticlePubMedGoogle Scholar
- Morita H, Wu J, Zipes DP: The QT syndromes: long and short. Lancet. 2008, 372: 750-763. 10.1016/S0140-6736(08)61307-0.View ArticlePubMedGoogle Scholar
- Perrin MJ, Subbiah RN, Vandenberg JI, Hill AP: Human ether-a-go-go-related gene (hERG) K+ channels: function and dysfunction. Prog Biophys Mol Biol. 2008, 98: 137-148. 10.1016/j.pbiomolbio.2008.10.006.View ArticlePubMedGoogle Scholar
- Saenen JB, Vrints JC: Molecular aspects of the congenital and acquired long QT syndrome: clinical implications. J Mol Cell Cardiol. 2008, 44: 633-646. 10.1016/j.yjmcc.2008.01.006.View ArticlePubMedGoogle Scholar
- Stone JM, Pilowsky LS: Novel targets for drugs in schizophrenia. CNS Neurol Disord Drug Targets. 2007, 6: 265-272. 10.2174/187152707781387323.View ArticlePubMedGoogle Scholar
- Weiden PJ: EPS profiles: the atypical antipsychotics are not all the same. J Psychiatr Pract. 2007, 13: 13-24. 10.1097/00131746-200701000-00003.View ArticlePubMedGoogle Scholar
- Kim DH, Maneen MJ, Stahl SM: Building a better antipsychotic: receptor targets for the treatment of multiple symptom dimensions of schizophrenia. Neurotherapeutics. 2009, 6: 78-85. 10.1016/j.nurt.2008.10.020.View ArticlePubMedGoogle Scholar
- Huffaker SJ, Chen J, Nicodemus KK, Sambataro F, Yang F, Mattay V, Lipska BK, Hyde TM, Song J, Rujescu D, Giegling I, Mayilyan K, Proust MJ, Soghoyan A, Caforio G, Callicott JH, Bertolino A, Meyer-Lindenberg A, Chang J, Ji Y, Egan MF, Goldberg TE, Kleinman JE, Lu B, Weinberger DR: A primate-specific, brain isoform of KCNH2 affects cortical physiology, cognition, neuronal repolarization and risk of schizophrenia. Nat Med. 2009, 15: 509-518. 10.1038/nm.1962.PubMed CentralView ArticlePubMedGoogle Scholar
- American Psychiatric Association: Diagnostic and statistical manual of mental disorders. 1994, Washington DC: American Psychiatric Association, 4Google Scholar
- Goldenberg I, Zareba W, Moss AJ: Long QT syndrome. Curr Probl Cardiol. 2008, 33: 629-694. 10.1016/j.cpcardiol.2008.07.002.View ArticlePubMedGoogle Scholar
- International Conference on Harmonisation: Guidance for industry: E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. 2005, Rockville: US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and ResearchGoogle Scholar
- International Conference on Harmonisation: ICH Topic E14: the clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. 2005, London: European Medicines AgencyGoogle Scholar
- Pfeufer A, Jalilzadeh S, Perz S, Mueller JC, Hinterseer M, Illig T, Akyol M, Huth C, Schopfer-Wendels A, Kuch B, Steinbeck G, Holle R, Nabauer M, Wichmann HE, Meitinger T, Kaab S: Common variants in myocardial ion channel genes modify the QT interval in the general population: results from the KORA study. Circ Res. 2005, 96: 693-701. 10.1161/01.RES.0000161077.53751.e6.View ArticlePubMedGoogle Scholar
- KBiosciences. http://kbioscience.co.uk
- International HapMap Project. http://hapmap.ncbi.nlm.nih.gov
- Jindal RD, Keshavan MS: Neurobiology of the early course of schizophrenia. Expert Rev Neurother. 2008, 8: 1093-1100. 10.1586/14737126.96.36.1993.View ArticlePubMedGoogle Scholar
- Lang UE, Puls I, Muller DJ, Strutz-Seebohm N, Gallinat J: Molecular mechanisms of schizophrenia. Cell Physiol Biochem. 2007, 20: 687-702. 10.1159/000110430.View ArticlePubMedGoogle Scholar
- Guasti L, Cilia E, Crociani O, Hofmann G, Polvani S, Becchetti A, Wanke E, Tempia F, Arcangeli A: Expression pattern of the ether-a-go-go-related (ERG) family proteins in the adult mouse central nervous system: evidence for coassembly of different subunits. J Comp Neurol. 2005, 491: 157-174. 10.1002/cne.20721.View ArticlePubMedGoogle Scholar
- Saganich MJ, Machado E, Rudy B: Differential expression of genes encoding subthreshold-operating voltage-gated K+ channels in brain. J Neurosci. 2001, 21: 4609-4624.PubMedGoogle Scholar
- Hirdes W, Schweizer M, Schuricht KS, Guddat SS, Wulfsen I, Bauer CK, Schwarz JR: Fast erg K+ currents in rat embryonic serotonergic neurones. J Physiol. 2005, 564: 33-49. 10.1113/jphysiol.2004.082123.PubMed CentralView ArticlePubMedGoogle Scholar
- Wimmers S, Bauer CK, Schwarz JR: Biophysical properties of heteromultimeric erg K+ channels. Pflugers Arch. 2002, 445: 423-430. 10.1007/s00424-002-0936-4.View ArticlePubMedGoogle Scholar
- Hardman RM, Forsythe ID: Ether-a-go-go-related gene K+ channels contribute to threshold excitability of mouse auditory brainstem neurons. J Physiol. 2009, 587: 2487-2497. 10.1113/jphysiol.2009.170548.PubMed CentralView ArticlePubMedGoogle Scholar
- Chiesa N, Rosati B, Arcangeli A, Olivotto M, Wanke E: A novel role for HERG K+ channels: spike-frequency adaptation. J Physiol. 1997, 501: 313-318. 10.1111/j.1469-7793.1997.313bn.x.PubMed CentralView ArticlePubMedGoogle Scholar
- Einarsen K, Calloe K, Grunnet M, Olesen SP, Schmitt N: Functional properties of human neuronal Kv11 channels. Pflugers Arch. 2009, 458: 689-700. 10.1007/s00424-009-0651-5.View ArticlePubMedGoogle Scholar
- Pessia M, Servettini I, Panichi R, Guasti L, Grassi S, Arcangeli A, Wanke E, Pettorossi VE: ERG voltage-gated K+ channels regulate excitability and discharge dynamics of the medial vestibular nucleus neurones. J Physiol. 2008, 586: 4877-4890. 10.1113/jphysiol.2008.155762.PubMed CentralView ArticlePubMedGoogle Scholar
- Sacco T, Bruno A, Wanke E, Tempia F: Functional roles of an ERG current isolated in cerebellar purkinje neurons. J Neurophysiol. 2003, 90: 1817-1828. 10.1152/jn.00104.2003.View ArticlePubMedGoogle Scholar
- Nedergaard S: A Ca2+-independent slow afterhyperpolarization in substantia nigra compacta neurons. Neuroscience. 2004, 125: 841-852. 10.1016/j.neuroscience.2004.02.030.View ArticlePubMedGoogle Scholar
- Canavier CC, Oprisan SA, Callaway JC, Ji H, Shepard PD: Computational model predicts a role for ERG current in repolarizing plateau potentials in dopamine neurons: implications for modulation of neuronal activity. J Neurophysiol. 2007, 98: 3006-3022. 10.1152/jn.00422.2007.View ArticlePubMedGoogle Scholar
- Crociani O, Cherubini A, Piccini E, Polvani S, Costa L, Fontana L, Hofmann G, Rosati B, Wanke E, Olivotto M, Arcangeli A: erg gene(s) expression during development of the nervous and muscular system of quail embryos. Mech Dev. 2000, 95: 239-243. 10.1016/S0925-4773(00)00335-X.View ArticlePubMedGoogle Scholar
- Feuk L, Carson AR, Scherer SW: Structural variation in the human genome. Nat Rev Genet. 2006, 7: 85-97. 10.1038/nrg1767.View ArticlePubMedGoogle Scholar
- Henrichsen CN, Chaignat E, Reymond A: Copy number variants, diseases and gene expression. Hum Mol Genet. 2009, 18 (Review Issue 1): R1-R8. 10.1093/hmg/ddp011.View ArticlePubMedGoogle Scholar
- Reynolds GP: Receptor mechanisms in the treatment of schizophrenia. J Psychopharmacol. 2004, 18: 340-345. 10.1177/026988110401800303.View ArticlePubMedGoogle Scholar
- Miyamoto S, Duncan GE, Marx CE, Lieberman JA: Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry. 2005, 10: 79-104. 10.1038/sj.mp.4001556.View ArticlePubMedGoogle Scholar
- Kang J, Chen XL, Rampe D: The antipsychotic drugs sertindole and pimozide block erg3, a human brain K+ channel. Biochem Biophys Res Commun. 2001, 286: 499-504. 10.1006/bbrc.2001.5434.View ArticlePubMedGoogle Scholar
- Rampe D, Murawsky MK, Grau J, Lewis EW: The antipsychotic agent sertindole is a high affinity antagonist of the human cardiac potassium channel HERG. J Pharmacol Exp Ther. 1998, 286: 788-793.PubMedGoogle Scholar
- Shepard PD, Canavier CC, Levitan ES: Ether-a-go-go-related gene potassium channels: what's all the buzz about?. Schizophr Bull. 2007, 33: 1263-1269. 10.1093/schbul/sbm106.PubMed CentralView ArticlePubMedGoogle Scholar
- Richtand NM, McNamara RK: Serotonin and dopamine interactions in psychosis prevention. Prog Brain Res. 2008, 172: 141-153. full_text.View ArticlePubMedGoogle Scholar
- Craddock N, O'Donovan MC, Owen MJ: Psychosis genetics: modeling the relationship between schizophrenia, bipolar disorder, and mixed (or "schizoaffective") psychoses. Schizophr Bull. 2009, 35: 482-490. 10.1093/schbul/sbp020.PubMed CentralView ArticlePubMedGoogle Scholar
- Tan HY, Callicott JH, Weinberger DR: Intermediate phenotypes in schizophrenia genetics redux: is it a no brainer?. Mol Psychiatry. 2008, 13: 233-238. 10.1038/sj.mp.4002145.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.